Jason Zemansky
Stock Analyst at B of A Securities
(4.87)
# 74
Out of 4,989 analysts
42
Total ratings
80%
Success rate
47.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $8 | $2.08 | +285.54% | 5 | Aug 25, 2025 | |
| RCKT Rocket Pharmaceuticals | Upgrades: Buy | $4 → $10 | $3.32 | +201.20% | 2 | Aug 20, 2025 | |
| INSM Insmed | Maintains: Buy | $94 → $109 | $141.00 | -22.70% | 10 | Jun 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | $32 → $18 | $15.75 | +14.29% | 2 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $62 → $54 | $48.29 | +11.82% | 4 | Apr 15, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $24.41 | +27.00% | 4 | Apr 1, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $12.51 | +35.89% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $8.38 | +246.06% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $15.01 | +106.53% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $2.43 | +2.88% | 5 | Jun 20, 2024 |
Werewolf Therapeutics
Aug 25, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.08
Upside: +285.54%
Rocket Pharmaceuticals
Aug 20, 2025
Upgrades: Buy
Price Target: $4 → $10
Current: $3.32
Upside: +201.20%
Insmed
Jun 11, 2025
Maintains: Buy
Price Target: $94 → $109
Current: $141.00
Upside: -22.70%
Keros Therapeutics
Jun 10, 2025
Downgrades: Neutral
Price Target: $32 → $18
Current: $15.75
Upside: +14.29%
Cytokinetics
Apr 15, 2025
Maintains: Neutral
Price Target: $62 → $54
Current: $48.29
Upside: +11.82%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $24.41
Upside: +27.00%
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $12.51
Upside: +35.89%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.38
Upside: +246.06%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $15.01
Upside: +106.53%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.43
Upside: +2.88%